PLUS1
53.75
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Market Closed
| Volume | 0.00 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Galapagos NV (PK) | GLPGF | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 53.75 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 53.75 | 53.75 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0.00 | - | 48.55 - 64.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 53.75 | USD |
Period:
Draw Mode:
Galapagos NV (PK) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.44B | 26.77M | - | $ - | $ - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 196.82k | $ - | - | - | - |
Galapagos NV (PK) News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GLPGF Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 3 Months | 54.25 | 54.25 | 53.75 | 53.90 | 34 | -0.50 | -0.92% |
| 6 Months | 64.00 | 64.00 | 53.75 | 60.83 | 12,496 | -10.25 | -16.02% |
| 1 Year | 58.1838 | 64.00 | 48.55 | 55.09 | 6,403 | -4.43 | -7.62% |
| 3 Years | 170.00 | 276.21 | 48.55 | 127.73 | 5,308 | -116.25 | -68.38% |
| 5 Years | 86.25 | 276.21 | 48.55 | 128.76 | 4,745 | -32.50 | -37.68% |
Galapagos NV (PK) Description
| Galapagos is a midsized biotechnology company, with therapeutic programs based on proprietary disease modifying drug targets, and a focus on inflammation, orphan disease, and anti-infectives. Galapagos' approach is to develop drugs that stop or reverse a disease state using novel targets that are identified through a patent protected target discovery platform. Galapagos also provides access to its target and drug discovery platform through its services division, BioFocus and Argenta, which offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies. |
